251 related articles for article (PubMed ID: 36040666)
21. Stereotactic ablative body radiotherapy with a central high dose using CyberKnife for metastatic lung tumors.
Hayashi K; Suzuki O; Shiomi H; Ono H; Setoguchi A; Nakai M; Nakanishi E; Tatekawa S; Ose N; Hirata T; Tamari K; Seo Y; Funaki S; Isohashi F; Shimizu S; Shintani Y; Ogawa K
BMC Cancer; 2023 Mar; 23(1):215. PubMed ID: 36882702
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study.
Sahin B; Atalar B; Kaytan Saglam E; Akgun Z; Abacioglu U; Arifoglu A; Ozyar E; Yaprak G; Ozseker Isik N; Guney Y; Caglar HB; Karaman S; Igdem S; Selek U; Berber T; Oner Dincbas F; Sengoz M; Yucel S; Demiral AN; Akyurek S
Clin Respir J; 2020 Nov; 14(11):1050-1059. PubMed ID: 32749053
[TBL] [Abstract][Full Text] [Related]
23. Correlation of biologically effective dose and the tumor control in Stage I (<5 cm) non-small cell lung cancer with stereotactic ablative radiotherapy: a single institutional cohort study.
Jeon W; Ahn SJ; Kim YC; Oh IJ; Park CK; Jeong JU; Yoon MS; Song JY; Nam TK; Chung WK
Jpn J Clin Oncol; 2018 Feb; 48(2):144-152. PubMed ID: 29194510
[TBL] [Abstract][Full Text] [Related]
24. MR-Linac guided adaptive stereotactic ablative body radiotherapy for recurrent cardiac sarcoma with mitral valve bioprosthesis - a case report.
Batumalai V; Carr M; Jameson M; Crawford D; Jelen U; Pagulayan C; Twentyman T; Hong A; de Leon J
J Med Radiat Sci; 2023 Jun; 70(2):199-205. PubMed ID: 36890690
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.
Chaudhuri AA; Tang C; Binkley MS; Jin M; Wynne JF; von Eyben R; Hara WY; Trakul N; Loo BW; Diehn M
Lung Cancer; 2015 Jul; 89(1):50-6. PubMed ID: 25997421
[TBL] [Abstract][Full Text] [Related]
26. Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer.
Dubaere E; Goffaux M; Wanet M; Bihin B; Gheldof C; Demoulin AS; Bolly A; Bustin F; Duplaquet F; Baugnee PE; Gustin M; Hers V; Maisin F; Marchand E; Ocak S; Pirard L; Vancutsem O; Van Neck E; Vandermoten G; Zaharia L; Remouchamps V
BMC Cancer; 2019 Jun; 19(1):639. PubMed ID: 31253136
[TBL] [Abstract][Full Text] [Related]
27. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
[TBL] [Abstract][Full Text] [Related]
28. Dosimetric feasibility of brain stereotactic radiosurgery with a 0.35 T MRI-guided linac and comparison vs a C-arm-mounted linac.
Slagowski JM; Redler G; Malin MJ; Cammin J; Lobb EC; Lee BH; Sethi A; Roeske JC; Flores-Martinez E; Stevens T; Yenice KM; Green O; Mutic S; Aydogan B
Med Phys; 2020 Nov; 47(11):5455-5466. PubMed ID: 32996591
[TBL] [Abstract][Full Text] [Related]
29. Distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a quantitative analysis of CT density changes.
Mattonen SA; Palma DA; Haasbeek CJ; Senan S; Ward AD
Acta Oncol; 2013 Jun; 52(5):910-8. PubMed ID: 23106174
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
Chang JY; Liu H; Balter P; Komaki R; Liao Z; Welsh J; Mehran RJ; Roth JA; Swisher SG
Radiat Oncol; 2012 Sep; 7():152. PubMed ID: 22963661
[TBL] [Abstract][Full Text] [Related]
31. Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial.
Gensheimer MF; Gee H; Shirato H; Taguchi H; Snyder JM; Chin AL; Vitzthum LK; Maxim PG; Wakelee HA; Neal J; Das M; Chang DT; Kidd E; Hancock SL; Shultz DB; Horst KC; Le QT; Wong S; Brown E; Nguyen N; Liang R; Loo BW; Diehn M
JAMA Oncol; 2023 Nov; 9(11):1525-1534. PubMed ID: 37707820
[TBL] [Abstract][Full Text] [Related]
32. Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC).
Palma DA; Nguyen TK; Kwan K; Gaede S; Landis M; Malthaner R; Fortin D; Louie AV; Frechette E; Rodrigues GB; Yaremko B; Yu E; Dar AR; Lee TY; Gratton A; Warner A; Ward A; Inculet R
Radiat Oncol; 2017 Jan; 12(1):30. PubMed ID: 28129789
[TBL] [Abstract][Full Text] [Related]
33. Long-term Overall Survival Outcomes in Patients with Early Stage, Peripherally Located, Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy in a Non-academic Cancer Centre.
Wood A; Aynsley E; Kumar G; Masinghe S; Anderson M; Veeratterapillay J; Huntley C; Blower A; Green J; Johnson D; Daniel J; Curtis H; Reynolds J; Turnbull M; Harland K; Swingler A; Banham E; Burke K; Bradley J; Greenhalgh A; Peedell C
Clin Oncol (R Coll Radiol); 2021 May; 33(5):283-291. PubMed ID: 33341333
[TBL] [Abstract][Full Text] [Related]
34. MLC tracking for lung SABR reduces planning target volumes and dose to organs at risk.
Caillet V; Keall PJ; Colvill E; Hardcastle N; O'Brien R; Szymura K; Booth JT
Radiother Oncol; 2017 Jul; 124(1):18-24. PubMed ID: 28655454
[TBL] [Abstract][Full Text] [Related]
35. Variability of Gross Tumor Volume Delineation for Stereotactic Body Radiotherapy of the Lung With Tri-
Wee CW; An HJ; Kang HC; Kim HJ; Wu HG
Technol Cancer Res Treat; 2018 Jan; 17():1533033818787383. PubMed ID: 30012039
[TBL] [Abstract][Full Text] [Related]
36. Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy.
Ayoub Z; Ning MS; Brooks ED; Kang J; Welsh JW; Chen A; Gandhi S; Heymach JV; Vaporciyan AA; Chang JY
Int J Radiat Oncol Biol Phys; 2020 Jun; 107(2):261-269. PubMed ID: 32044413
[TBL] [Abstract][Full Text] [Related]
37. Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy.
Dosani M; Yang R; McLay M; Wilson D; Liu M; Yong-Hing CJ; Hamm J; Lund CR; Olson R; Schellenberg D
Curr Oncol; 2019 Feb; 26(1):e57-e63. PubMed ID: 30853810
[TBL] [Abstract][Full Text] [Related]
38. Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer.
Sumodhee S; Bondiau PY; Poudenx M; Cohen C; Naghavi AO; Padovani B; Maneval D; Gal J; Leysalle A; Ghalloussi H; Otto J; Doyen J
BMC Cancer; 2019 Apr; 19(1):305. PubMed ID: 30943943
[TBL] [Abstract][Full Text] [Related]
39. Survey of the Patterns of Using Stereotactic Ablative Radiotherapy for Early-Stage Non-small Cell Lung Cancer in Korea.
Song S; Chang JH; Kim HJ; Kim YS; Kim JH; Ahn YC; Kim JS; Song SY; Moon SH; Cho MJ; Youn SM
Cancer Res Treat; 2017 Jul; 49(3):688-694. PubMed ID: 27809459
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort.
Soldà F; Lodge M; Ashley S; Whitington A; Goldstraw P; Brada M
Radiother Oncol; 2013 Oct; 109(1):1-7. PubMed ID: 24128806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
